Corona Remedies IPO gets massive buzz, listing December 14
Corona Remedies's IPO just wrapped up and it was a total hit—subscribed 137 times in only three days and raising ₹655.37 crore.
Even though the company didn't get fresh funds (it was an offer for sale), shares are already trading at a 30% premium in the gray market, so investor excitement is definitely high.
Why everyone's watching this stock
Experts think Corona Remedies will debut strong on Dalal Street, with expected listing prices about 25-27% higher than the issue price.
The company has been growing much faster than most pharma players—its sales grew nearly twice as fast as the industry average from 2022 to 2025.
Analysts say it's smart to book some profits early but hang onto some shares if you're thinking long-term, since their focus on chronic therapies looks promising.